These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30864295)

  • 21. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    Park SE; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Thorac Oncol; 2018 Jan; 13(1):106-111. PubMed ID: 29101058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Shoushtari AN; Bluth MJ; Goldman DA; Bitas C; Lefkowitz RA; Postow MA; Munhoz RR; Buchar G; Hester RH; Romero JA; Fitzpatrick LJ; Weiser MR; Panageas KS; Wolchok JD; Chapman PB; Carvajal RD
    Melanoma Res; 2017 Feb; 27(1):57-64. PubMed ID: 27792058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Afzal MZ; Shirai K
    Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Primary malignant melanoma of the esophagus--detection of circulating tumor cells].
    Fujii K; Goto A; Matsunaga Y; Hasegawa Y; Sukawa Y; Suzuki K; Yonezawa K; Abe T; Itoh A; Shinomura Y; Iimura Y; Hasegawa N; Nakamura H; Yoshida Y
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1539-43. PubMed ID: 20716882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
    Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
    Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
    Heidelberger V; Goldwasser F; Kramkimel N; Jouinot A; Franck N; Arrondeau J; Guégan S; Mansuet-Lupo A; Alexandre J; Damotte D; Avril MF; Dupin N; Aractingi S
    Invest New Drugs; 2017 Dec; 35(6):842-847. PubMed ID: 28569347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
    Karachaliou GS; Ayvali F; Collichio FA; Lee CB; Ivanova A; Ollila DW; Moschos SJ
    Oncology; 2020; 98(3):174-178. PubMed ID: 31794964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.
    Saint-Jean M; Fronteau C; Peuvrel L; Khammari A; Varey E; Quéreux G; Dréno B
    Medicine (Baltimore); 2020 Jul; 99(29):e21329. PubMed ID: 32702928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.
    Rochefort P; Roussel J; de la Fouchardière A; Sarabi M; Desseigne F; Guibert P; Cattey-Javouhey A; Mastier C; Neidhardt-Berard EM; de la Fouchardière C
    Immunotherapy; 2018 Aug; 10(10):831-835. PubMed ID: 30073896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
    Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
    Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma.
    Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q
    Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary malignant melanoma of the esophagus].
    Kato N; Kamino K; Yamashita T; Umeyama K; Mitsuhashi T
    Gan No Rinsho; 1986 Sep; 32(11):1459-65. PubMed ID: 3773274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Long Surviving Case of Multiple Early Stage Primary Malignant Melanoma of the Esophagus and a Review of the Literature.
    Yamamoto S; Makuuchi H; Kumaki N; Ozawa S; Shimada H; Chino O; Kazuno A; Yasuda S; Tamayama T; Sakai I
    Tokai J Exp Clin Med; 2015 Sep; 40(3):90-5. PubMed ID: 26369261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.